The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Shares of Medtronic (NYSE: MDT) are off to a fantastic start in 2025, already rising by 13% year to date. The medical devices ...

Medical device specialist Medtronic ( MDT 1.05%) has long been a solid dividend stock -- and it has upped its payout for ...

Medtronic's next-gen renal denervation catheter and procedure are in the works to advance the FDA-approved Symplicity Spyral ...

Medtronic's MiniMed 670G - the closest thing yet to an artificial pancreas - has been launched in the US. The so-called 'hybrid closed-loop' system comprises a blood glucose sensor ...

Medtronic's MiniMed 670G hybrid closed loop system has been hailed as a long-awaited breakthrough, as many people with type 1 diabetes and their families have been calling for such a device for years.

The platform, which includes the new form factor CGM and the Simplera Sync sensor, is designed for integration with Medtronic ...

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in ...

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

Medtronic said on Tuesday it will appoint Renault's finance chief Thierry Piéton as its chief financial officer, effective ...

Kuros Biosciences USA entered into a five-year exclusive sales agency agreement with Medtronic spinal division.